目的 探討吉西他濱聯(lián)合順鉑對肺癌的臨床治療效果及安全性評估。方法 選取2017年1月—2018年2月在廣州軍區(qū)廣州總醫(yī)院住院治療的肺癌患者90例，采用隨機數(shù)字法分為對照組和觀察組，每組各45例。對照組患者給予多西他賽聯(lián)合順鉑進行化療，觀察組患者給予吉西他濱聯(lián)合順鉑進行化療。觀察兩組患者的臨床治療有效率、疾病控制率及不良反應(yīng)發(fā)生率，并比較化療前后兩組的QOL評分及KPS評分。結(jié)果 治療后，觀察組治療有效率和疾病控制率分別為84.44%和91.11%，對照組患者的治療有效率和疾病控制率分別為62.22%和73.33%，差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組QOL評分及KPS評分均升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05），且觀察組患者的QOL評分及KPS評分均顯著高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。兩組患者在胃腸道反應(yīng)、骨髓抑制、血小板減少、乏力、貧血及發(fā)熱等不良反應(yīng)上相比，差異無統(tǒng)計學(xué)意義。結(jié)論 吉西他濱聯(lián)合順鉑治療肺癌的臨床效果較好，且安全性較高，值得推廣應(yīng)用。

Objective To investigate the clinical therapeutic effect and safety asserrment of gemcitabine combined with cisplatin in treatment of lung cancer. Methods Patients (90 cases) with lung cancer in General Hospital of Guangzhou Military Command from January 2017 to February 2018 were divided into control group and observation group, according to random number method, and each group had 45 cases. Patients in control group was given docetaxel combined with cisplatin by chemotherapy, patients in the observation group was given gemcitabine combined with cisplatin by chemotherapy. The clinical efficiency, disease control rate, and adverse reaction rate in two groups were observed, and QOL score and KPS score before and after chemotherapy were compared. Results After treatment, the effective clinical treatment and disease control rate in the observation group were 84.44% and 91.11%, respectively, and the effective clinical treatment and disease control rate in the control group were 62.22% and 73.33%, respectively, the difference was statistically significant (P<0.05). Before treatment, the QOL score and KPS score in two groups were significantly increased, and there were differences in the same group (P<0.05). And the QOL score and KPS score in the observation group were significantly higher than those in the control group, and there were differences between two groups (P<0.05). Compared with the adverse reaction such as gastrointestinal reaction, myelosuppression, thrombocytopenia, weak, anemia and fever between two groups, the difference was not statistically significant. Conclusion Gemcitabine combined with cisplatin has good effect in treatment of lung cancer, and the safety is high, worthy of promotion and application.